Seyed Ali Mirshahvalad

Dr. Seyed Ali Mirshahvalad

University Health Network, Toronto, Ontario, Canada
orcid
Nuclear Radiologist

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
ASAlireza Safarian
Alireza Safarian
Seyed Ali MirshahvaladSeyed Ali Mirshahvalad
Seyed Ali Mirshahvalad
HNHadi Nasrollahi
Hadi Nasrollahi
TJTheresa Jung
Theresa Jung
CPChristian Pirich
Christian Pirich
MBMohsen Beheshti
Mohsen Beheshti
Lung cancer remains one of the most prevalent cancers globally and the leading cause of cancer-related deaths, accounting for nearly one-fifth of all cancer fatalities. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) plays a vital role in assessing lung cancer and managing disease progression. While traditional PET/CT imaging relies on qualitative analysis and basic quantitative parameters, radiomics offers a more advanced approach to analyzing tumor phenotypes. Recently, radiomics has gained attention for its potential to enhance the prognostic and diagnostic capabilities of [18F]FDG PET/CT in various cancers. This review explores the expanding role of [18F]FDG PET/CT-based radiomics, particularly when integrated with artificial intelligence (AI), in managing lung cancer, especially non-small cell lung cancer (NSCLC). We review how radiomics and AI improve diagnostics, staging, tumor subtype identification, and molecular marker detection, which influence treatment decisions. Additionally, we address challenges in clinical integration, such as imaging protocol standardization, feature reproducibility, and the need for extensive prospective studies. Ultimately, radiomics and AI hold great promise for enabling more personalized and effective lung cancer treatments, potentially transforming disease management.

3 January 2024 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
NZNazanin Zamani-Siahkali
Nazanin Zamani-Siahkali
Seyed Ali MirshahvaladSeyed Ali Mirshahvalad
Seyed Ali Mirshahvalad
AFAbolfazl Farbod
Abolfazl Farbod
GDGhasemali Divband
Ghasemali Divband
CPChristian Pirich
Christian Pirich
MBMohsen Beheshti
Mohsen Beheshti
Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [18F]F-FDG and [18F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [99mTc]Tc-PSMA, [68Ga]Ga-PSMA, or [11C]C- or [18F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.

12 November 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MCMohammadreza Chavoshi
Mohammadreza Chavoshi
Seyed Ali MirshahvaladSeyed Ali Mirshahvalad
Seyed Ali Mirshahvalad
UMUr Metser
Ur Metser
PVPatrick Veit-Haibach
Patrick Veit-Haibach

16 June 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Seyed Ali MirshahvaladSeyed Ali Mirshahvalad
Seyed Ali Mirshahvalad
RHRicarda Hinzpeter
Ricarda Hinzpeter
AKAndres Kohan
Andres Kohan
RAReut Anconina
Reut Anconina
RKRoshini Kulanthaivelu
Roshini Kulanthaivelu
PVPatrick Veit-Haibach
Patrick Veit-Haibach

2 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NZNazanin Zamani-Siahkali
Nazanin Zamani-Siahkali
Seyed Ali MirshahvaladSeyed Ali Mirshahvalad
Seyed Ali Mirshahvalad
CPChristian Pirich
Christian Pirich
MBMohsen Beheshti
Mohsen Beheshti
We described the diagnostic performance of [18F]F-FDG-PET in malignant melanoma by conducting a comprehensive systematic review and meta-analysis of the existing literature. The study was designed following PRISMA-DTA. Original articles with adequate crude data for meta-analytic calculations that evaluated [18F]F-FDG-PET and compared it with a valid reference standard were considered eligible. The pooled measurements were calculated based on the data level (patient/lesion-based). Regarding sub-groups, diagnostic performances were calculated for local, regional and distant involvement. The bivariate model was employed to calculate sensitivity and specificity. The initial search resulted in 6678 studies. Finally, 100 entered the meta-analysis, containing 82 patient-based (10,403 patients) and 32 lesion-based (6188 lesions) datasets. At patient level, overall, [18F]F-FDG-PET had pooled sensitivity and specificity of 81% (95%CI: 73–87%) and 92% (95%CI: 90–94%), respectively. To detect regional lymph node metastasis, the pooled sensitivity and specificity were 56% (95%CI: 40–72%) and 97% (95%CI: 94–99%), respectively. To detect distant metastasis, they were 88% (95%CI: 81–93%) and 94% (95%CI: 91–96%), respectively. At lesion level, [18F]F-FDG-PET had a pooled sensitivity and specificity of 70% (95%CI: 57–80%) and 94% (95%CI: 88–97%), respectively. Thus, [18F]F-FDG-PET is a valuable diagnostic modality for melanoma assessment. It was accurate in various clinical scenarios. However, despite its high specificity, it showed low sensitivity in detecting regional lymph node metastasis and could not replace lymph node biopsy.

14 July 2024 in Academic Radiology
Verified
Journal Article
Open access
RHRicarda Hinzpeter
Ricarda Hinzpeter
RKRoshini Kulanthaivelu
Roshini Kulanthaivelu
AKAndres Kohan
Andres Kohan
VMVanessa Murad
Vanessa Murad
Seyed Ali MirshahvaladSeyed Ali Mirshahvalad
Seyed Ali Mirshahvalad
PVPatrick Veit-Haibach
Patrick Veit-Haibach
To investigate whether [18F]-FDG PET/CT-derived radiomics may correlate with driver gene mutations in non-small cell lung cancer (NSCLC) patients. In this IRB-approved retrospective study, 203 patients with surgically treated NSCLC who underwent subsequent genomic analysis of the primary tumour at our institution between December 2004 and January 2014 were identified. Of those, 128 patients (mean age 62.4 ± 10.8 years; range: 35-84) received preoperative [18F]-FDG PET/CT as part of their initial staging and thus were included in the study. PET and CT image segmentation and feature extraction were performed semi-automatically with an open-source software platform (LIFEx, Version 6.30, lifexsoft.org). Molecular profiles using different next-generation sequencing (NGS) panels were collected from a web-based resource (cBioPortal.ca for Cancer genomics). Two statistical models were then built to evaluate the predictive ability of [18F]-FDG PET/CT-derived radiomics features for driver gene mutations in NSCLC. More than half (68/128, 53%) of all tumour samples harboured three or more gene mutations. Overall, 55% of tumour samples demonstrated a mutation in TP53, 26% of samples had alterations in KRAS and 17% in EGFR. Extensive statistical analysis resulted in moderate to good predictive ability. The highest Youden Index for TP53 was achieved using combined PET/CT features (0.70), for KRAS using PET features only (0.57) and for EGFR using CT features only (0.60). Our study demonstrated a moderate to good correlation between radiomics features and driver gene mutations in NSCLC, indicating increased predictive ability of genomic profiles using combined [18F]-FDG PET/CT-derived radiomics features.